GAD1 and diabetes mellitus: In the UKPDS3 study, the prevalence of antibodies against pancreatic islets (anti-glutamic acid decarboxylase-Anti-GAD-) was 12% of all patients with T2DM, although the prevalence in patients diagnosed with DM before the age of 35 years could reach 34% [3].